University of Rochester receives funding for HIV vaccine development
The funds, which were donated by the National Institutes of Health (NIH), will be used only for HIV vaccine development. The NIH is looking for innovative, high-risk, high-impact research that will change how the medical industry develops vaccines.
“Eliminating the virus where it first comes in contact with the body is critical to the development of an effective vaccine,” Michael Keefer, an infectious diseases professor who has more than 20 years of experience in the preventive HIV vaccine field, said. “This research will help us understand, in greater detail than ever before, why some HIV vaccines are partially effective while others are not, and will allow us to identify strategies to include in the development of future HIV vaccines.”
As of today, an effective, safe, and durable HIV vaccine has not yet been developed.
“These projects bring together a very talented team of researchers and clinicians to understand how humans respond to HIV vaccines at their most vulnerable sites,” James Kobie, an assistant professor in the department, said. “I am very excited to translate the knowledge we obtain into new HIV vaccine strategies.”